Flagship Pioneering Introduces a New Bioplatform Company Abiologics

Flagship Pioneering Introduces a New Bioplatform Company Abiologics

By, Admin 25 July 2024

Flagship Pioneering Introduces Abiologics: Revolutionizing Biotherapeutics with Advanced Capabilities

Overview

Flagship Pioneering has introduced Abiologics, a new bioplatform company that aims to transform the field of biologics through the development of a novel class of medicines called Synteins™. These Synteins are designed and synthesized using innovative building blocks, granting them unique properties that could lead to groundbreaking treatments for various diseases. Flagship has committed $50 million to advance Abiologics' platform and develop a broad pipeline of therapies, with initial efforts focused on oncology and immunology.

Words from Chairman: Abiologics

  • While biologics have made significant strides in medicine over the last forty years, their potential remains constrained by the natural limitations of current technologies,"" stated Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of Abiologics' Strategic Oversight Board. 
  • By integrating advancements in artificial intelligence, automated polymer synthesis, and chemical functionalization, we asked if it was possible to design biologics from entirely new building blocks to overcome these constraints.

Abiologics Operations

• Abiologics operates with a sophisticated digital and automated wet-lab infrastructure that enables the creation of advanced biologics with exceptional pharmacological properties. 

  • The platform uses state-of-the-art AI to design Synteins from a range of artificial building blocks, extending beyond the 20 natural amino acids used in current biologic drugs. 
  • This includes the use of D-amino acids, which are mirror images of natural amino acids. Abiologics then employs advanced chemical synthesis techniques to produce these designed Synteins. 
  • This approach allows for the development of Synteins that can target a wide array of therapeutic targets while avoiding the body's immune responses. 
  • Abiologics is the first to develop and scale polymers made entirely from artificial building blocks, including Synteins composed solely of D-amino acids, which can bind to diverse therapeutic targets with high stability. 

Words from the CEO: Abiologics

  • For the first time, we are able to produce biologics at scale with a high degree of programmability, offering a new class of medicines with the potential to revolutionize treatment,"" said Avak Kahvejian, Ph.D., Co-Founder and CEO of Abiologics and General Partner at Flagship Pioneering. 
  • By using artificial building blocks instead of natural amino acids, Synteins can evade immune system detection, leading to benefits such as less frequent dosing, potential for oral administration, and the ability to access previously unreachable areas of the body. Abiologics is poised to deliver innovative treatments for a range of diseases.

The Foundation Team

Abiologics' founding team includes Mike Hamill, Ph.D., Chief Innovation Officer, Kala Subramanian, Ph.D., Founding President, Jaclyn Dunphy, Ph.D., Senior Director of Strategy and Research Operations, and Alicia Kaestli, Ph.D., Senior Associate—all affiliated with Flagship Pioneering. Bradley Pentelute, Ph.D., Professor of Chemistry at MIT, is also an Academic Co-Founder.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!